When marketing and science intersect: do patients with MS benefit?

Affiliations

Comment

Fred D Lublin. Neurology. 2002.

. 2002 Nov 26;59(10):1480-1.

doi: 10.1212/wnl.59.10.1480.

¹ Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029-6574, USA. Fred.Lublin@mssm.edu

No abstract available

Comment in

Needed in MS: evidence, not EVIDENCE.
Kieburtz K, McDermott M. Kieburtz K, et al. Neurology. 2002 Nov 26;59(10):1482-3. doi: 10.1212/wnl.59.10.1482. Neurology. 2002. PMID: 12451186 No abstract available.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial.
Byrne E. Byrne E. Neurology. 2003 Jun 10;60(11):1872; author reply 1872-3. Neurology. 2003. PMID: 12796564 Clinical Trial. No abstract available.

Needed in MS: evidence, not EVIDENCE.
Kieburtz K, McDermott M. Kieburtz K, et al. Neurology. 2002 Nov 26;59(10):1482-3. doi: 10.1212/wnl.59.10.1482. Neurology. 2002. PMID: 12451186 No abstract available.
Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O'Connor P, Monaghan E, Li D, Weinshenker B; EVIDENCE Study Group. EVidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Panitch H, et al. Neurology. 2002 Nov 26;59(10):1496-506. doi: 10.1212/01.wnl.0000034080.43681.da. Neurology. 2002. PMID: 12451188 Clinical Trial.
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, Kooijmans-Coutinho MF, Tsao EC, Sandrock AW; European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators. Clanet M, et al. Neurology. 2002 Nov 26;59(10):1507-17. doi: 10.1212/01.wnl.0000032256.35561.d6. Neurology. 2002. PMID: 12451189 Clinical Trial.